PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 281 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $7,537,403 | +108853.5% | 184,695 | +3.1% | 0.22% | +0.5% |
| Q4 2022 | $6,918 | -99.9% | 179,174 | +19.1% | 0.22% | -16.2% |
| Q3 2022 | $8,003,000 | +4.7% | 150,462 | +14.8% | 0.26% | +12.6% |
| Q2 2022 | $7,644,000 | -23.7% | 131,120 | -0.1% | 0.23% | -3.0% |
| Q1 2022 | $10,015,000 | -4.9% | 131,229 | -25.0% | 0.24% | +12.3% |
| Q4 2021 | $10,530,000 | +21.4% | 175,011 | +13.0% | 0.21% | +17.2% |
| Q3 2021 | $8,677,000 | -22.9% | 154,940 | -16.4% | 0.18% | -10.9% |
| Q2 2021 | $11,249,000 | -17.1% | 185,375 | -4.3% | 0.20% | -19.8% |
| Q1 2021 | $13,571,000 | +2.7% | 193,625 | -12.3% | 0.25% | +0.4% |
| Q4 2020 | $13,208,000 | -8.7% | 220,722 | -8.3% | 0.25% | -34.6% |
| Q3 2020 | $14,471,000 | -5.8% | 240,696 | -17.8% | 0.38% | -12.1% |
| Q2 2020 | $15,368,000 | +36.6% | 292,898 | -12.7% | 0.44% | +8.4% |
| Q1 2020 | $11,250,000 | -25.9% | 335,519 | +0.1% | 0.40% | +4.1% |
| Q4 2019 | $15,178,000 | +17.6% | 335,062 | -1.2% | 0.39% | +10.3% |
| Q3 2019 | $12,904,000 | -0.7% | 338,964 | +13.5% | 0.35% | +9.3% |
| Q2 2019 | $12,993,000 | +41.0% | 298,761 | +23.4% | 0.32% | +39.6% |
| Q1 2019 | $9,212,000 | +6.5% | 242,028 | +20.3% | 0.23% | -5.7% |
| Q4 2018 | $8,653,000 | -21.7% | 201,139 | -10.5% | 0.24% | -6.9% |
| Q3 2018 | $11,046,000 | +27.4% | 224,747 | -16.9% | 0.26% | +20.7% |
| Q2 2018 | $8,672,000 | -14.6% | 270,573 | -17.0% | 0.22% | -12.5% |
| Q1 2018 | $10,157,000 | -39.3% | 326,056 | -11.1% | 0.25% | -37.1% |
| Q4 2017 | $16,735,000 | +10.3% | 366,603 | -9.3% | 0.39% | +8.2% |
| Q3 2017 | $15,175,000 | -10.5% | 404,141 | +13.8% | 0.36% | -13.7% |
| Q2 2017 | $16,947,000 | -0.1% | 355,282 | -0.3% | 0.42% | -2.1% |
| Q1 2017 | $16,960,000 | +42.6% | 356,296 | -3.2% | 0.43% | +39.5% |
| Q4 2016 | $11,892,000 | -4.0% | 368,169 | +1.7% | 0.31% | -4.3% |
| Q3 2016 | $12,385,000 | – | 361,930 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |